Aurobindo Pharma acquires 80% stake in Tergene Biotech

01 Mar 2025 Evaluate

Aurobindo Pharma has completed the acquisition of entire 80% of the equity share capital of Tergene Biotech, a step-down subsidiary of the Tergene and also a joint venture company, held by Auro Vaccines, a wholly owned stepdown subsidiary of the Aurobindo Pharma. The purchase consideration is of Rs 10.76 crore. Post this transaction, Tergene has become a direct subsidiary of the company.

Earlier on February 6, 2025, the company’s board had approved to purchase entire 80% of the equity share capital of Tergene Biotech. 

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1176.05 17.40 (1.50%)
03-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1770.10
Dr. Reddys Lab 1151.25
Cipla 1495.15
Lupin 2094.50
Zydus Lifesciences 901.05
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
Please wait your portfolio is updating...